Vivek Subbiah, MD, on Dabrafenib/Trametinib Efficacy in Biliary Tract Cancer

According to a recent study, led by Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, dabrafenib in combination with trametinib is an effective treatment option for patients with BRAFV600E -mutated biliary tract cancer (BTC). In an interview with i3 Health, Dr. Subbiah shares insights on the significance of these study results and unmet needs and future treatment in this patient population. What are the most challenging aspects of treating patients with BRAFV600E -mutated ...
Continue reading

Dabrafenib/Trametinib Effective in Mutated Biliary Tract Cancer

Patients with biliary tract cancer often experience disease relapse after gemcitabine-based chemotherapy, representing an area of need in this patient population. In 5% of biliary tract tumors, a mutation in the BRAF gene is found. Dabrafenib in combination with trametinib has been shown to be an effective treatment option for patients with BRAFV600E – mutated cancers, particularly those with biliary tract cancer, according to a recent study, results of which were published in The Lancet Oncolog...
Continue reading

Aspirin and Biliary Tract Cancer Survival: Sarah Jackson, PhD

​Biliary tract cancers have a dismal prognosis, with five-year survival rates ranging from 5% to 15%. In their publication in JAMA Oncology, Sarah S. Jackson, PhD, and colleagues report that aspirin increases survival in biliary tract cancers, including gallbladder cancer, cholangiocarcinoma, ampulla of Vater cancer, and overlapping lesions of the biliary tract. In this interview with i3 Health, Dr. Jackson discusses the potential ramifications of her study's findings. What led you to pursue thi...
Continue reading

In Biliary Tract Cancers, Aspirin Increases Survival

​Researchers have now revealed that aspirin can increase the dismal survival chances for biliary tract cancers. Because these rare diseases may not produce symptoms until the later stages, 60% to 70% of patients with biliary tract cancers present with later-stage disease. Less than 10% have resectable tumors at the time of diagnosis, and 50% present with lymph node metastasis. As a result, the median survival is under a year, with five-year survival rates ranging from 5% to 15%. "There is a crit...
Continue reading

Adjuvant Capecitabine Effective in Biliary Tract Cancer

​With a five-year overall survival rate under 10%, the outlook is poor for individuals diagnosed with biliary tract cancer. Only 20% of patients are eligible for surgical resection with the intent to cure the disease. In addition, until this point, no studies have identified a beneficial adjuvant therapy. In order to remedy this problem, the researchers of the BILCAP study (EudraCT 2005-003318-13), a phase 3 clinical trial featuring a collaboration of 44 specialist hepato-pancreato-biliary cente...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.